Mylan Urges FDA Not to Approve Advair Generics Based on Multi-Batch Studies

Drug Industry Daily
A A
The FDA should not approve generics of Glaxo Smith Kline’s asthma drug Advair Diskus that depend on multiple-batch studies to show pharmacokinetic bioequivalence, according to Mylan.

To View This Article:

Login

Subscribe To Drug Industry Daily